** Medical device maker Stryker SYK.N rise 1.2% to $395
** Brokerage Citi Research resumes coverage on SYK with "buy" rating; sets PT at $450, 15.3% upside to the stock's last close
** Brokerage says SYK has built a diversified business through multiple buys such as the $4.9 billion Inari medical acquisition, which added Inari's ClotTriever and FlowTriever devices that treat venous thromboembolism (VTE)
** VTE — a disease where blood clots form in veins — is estimated to impact more than 900,000 patients annually in the U.S., brokerage says
** SYK estimates the value of the VTE market at $15 billion globally, including $6 billion in the U.S.
** Citi calls the Inari acquisition "another step in SYK evolution"
** Stock has risen 10.7% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.